184 related articles for article (PubMed ID: 25593995)
1. Antagonistic analogs of growth hormone-releasing hormone increase the efficacy of treatment of triple negative breast cancer in nude mice with doxorubicin; A preclinical study.
Perez R; Schally AV; Popovics P; Cai R; Sha W; Rincon R; Rick FG
Oncoscience; 2014; 1(10):665-73. PubMed ID: 25593995
[TBL] [Abstract][Full Text] [Related]
2. Potentiating effects of GHRH analogs on the response to chemotherapy.
Schally AV; Perez R; Block NL; Rick FG
Cell Cycle; 2015; 14(5):699-704. PubMed ID: 25648497
[TBL] [Abstract][Full Text] [Related]
3. Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers.
Perez R; Schally AV; Vidaurre I; Rincon R; Block NL; Rick FG
Oncotarget; 2012 Sep; 3(9):988-97. PubMed ID: 22941871
[TBL] [Abstract][Full Text] [Related]
4. Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia.
Gaumond SI; Abdin R; Costoya J; Schally AV; Jimenez JJ
Oncotarget; 2024 Apr; 15():248-254. PubMed ID: 38588464
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and structure-activity studies on novel analogs of human growth hormone releasing hormone (GHRH) with enhanced inhibitory activities on tumor growth.
Zarandi M; Cai R; Kovacs M; Popovics P; Szalontay L; Cui T; Sha W; Jaszberenyi M; Varga J; Zhang X; Block NL; Rick FG; Halmos G; Schally AV
Peptides; 2017 Mar; 89():60-70. PubMed ID: 28130121
[TBL] [Abstract][Full Text] [Related]
6. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.
Bajo AM; Schally AV; Halmos G; Nagy A
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3742-8. PubMed ID: 14506166
[TBL] [Abstract][Full Text] [Related]
7. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.
Föst C; Duwe F; Hellriegel M; Schweyer S; Emons G; Gründker C
Oncol Rep; 2011 May; 25(5):1481-7. PubMed ID: 21331448
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of aerobic glycolysis enhances the anti-tumor efficacy of Zoptarelin Doxorubicin in triple-negative breast cancer cells.
Gründker C; Wokoun U; Hellriegel M; Emons G
J Obstet Gynaecol Res; 2019 Jul; 45(7):1334-1342. PubMed ID: 31016845
[TBL] [Abstract][Full Text] [Related]
9. Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers.
Klukovits A; Schally AV; Szalontay L; Vidaurre I; Papadia A; Zarandi M; Varga JL; Block NL; Halmos G
Cancer; 2012 Feb; 118(3):670-80. PubMed ID: 21751186
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of potent antagonists of receptors for growth hormone-releasing hormone with antitumor and anti-inflammatory activity.
Cai R; Zhang X; Wang H; Cui T; Halmos G; Sha W; He J; Popovics P; Vidaurre I; Zhang C; Mirsaeidi M; Schally AV
Peptides; 2022 Apr; 150():170716. PubMed ID: 34952135
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice.
Gründker C; Völker P; Griesinger F; Ramaswamy A; Nagy A; Schally AV; Emons G
Am J Obstet Gynecol; 2002 Sep; 187(3):528-37. PubMed ID: 12237622
[TBL] [Abstract][Full Text] [Related]
12. The effect of a novel antagonist of growth hormone releasing hormone on cell proliferation and on the key cell signaling pathways in nine different breast cancer cell lines.
Pozsgai E; Schally AV; Hocsak E; Zarandi M; Rick F; Bellyei S
Int J Oncol; 2011 Oct; 39(4):1025-32. PubMed ID: 21701777
[TBL] [Abstract][Full Text] [Related]
13. Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition.
Köster F; Engel JB; Schally AV; Hönig A; Schröer A; Seitz S; Hohla F; Ortmann O; Diedrich K; Buchholz S
Breast Cancer Res Treat; 2009 Jul; 116(2):273-9. PubMed ID: 18629632
[TBL] [Abstract][Full Text] [Related]
14. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
Seitz S; Buchholz S; Schally AV; Weber F; Klinkhammer-Schalke M; Inwald EC; Perez R; Rick FG; Szalontay L; Hohla F; Segerer S; Kwok CW; Ortmann O; Engel JB
BMC Cancer; 2014 Nov; 14():847. PubMed ID: 25410881
[TBL] [Abstract][Full Text] [Related]
15. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
Engel J; Emons G; Pinski J; Schally AV
Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
[TBL] [Abstract][Full Text] [Related]
16. The Application of GHRH Antagonist as a Treatment for Resistant APL.
Chale RS; Almeida SM; Rodriguez M; Jozic I; Gaumond SI; Schally AV; Jimenez JJ
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370714
[TBL] [Abstract][Full Text] [Related]
17. Effects of an Antagonistic Analog of Growth Hormone-Releasing Hormone on Endometriosis in a Mouse Model and In Vitro.
Köster F; Jin L; Shen Y; Schally AV; Cai RZ; Block NL; Hornung D; Marschner G; Rody A; Engel JB; Finas D
Reprod Sci; 2017 Nov; 24(11):1503-1511. PubMed ID: 28205459
[TBL] [Abstract][Full Text] [Related]
18. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
[TBL] [Abstract][Full Text] [Related]
19. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.
Seitz S; Rick FG; Schally AV; Treszl A; Hohla F; Szalontay L; Zarandi M; Ortmann O; Engel JB; Buchholz S
Oncol Rep; 2013 Jul; 30(1):413-8. PubMed ID: 23624870
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin analogue RC-160 and LH-RH antagonist SB-75 inhibit growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.
Radulovic S; Comaru-Schally AM; Milovanovic S; Schally AV
Pancreas; 1993 Jan; 8(1):88-97. PubMed ID: 8093555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
